Innogen Pharma's Efsubaglutide Manufacturing Sites Receive Brazil GMP Certification

MT Newswires Live

08/04

Guangzhou Innogen Pharmaceutical (HKG:2591) said two contract manufacturing sites for its Efsubaglutide Alfa injection project received good manufacturing practice (GMP) certification from Brazil's health regulator, ANVISA.

The certification confirms the sites comply with Pharmaceutical Inspection Co-operation Scheme GMP standards and is expected to support commercial production capacity as well as the drug's registration and commercialization in PIC/S member countries, according to a Monday Hong Kong bourse filing.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2656824855"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2656824855\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2656824855?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 13:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656824855","market":"hk","top_or_hot":-1,"title":"Innogen Pharma's Efsubaglutide Manufacturing Sites Receive Brazil GMP Certification","media":"MT Newswires Live","content":"<html><body><p> Guangzhou Innogen Pharmaceutical (HKG:2591) said two contract manufacturing sites for its Efsubaglutide Alfa injection project received good manufacturing practice (GMP) certification from Brazil's health regulator, ANVISA.</p><p>The certification confirms the sites comply with Pharmaceutical Inspection Co-operation Scheme GMP standards and is expected to support commercial production capacity as well as the drug's registration and commercialization in PIC/S member countries, according to a Monday Hong Kong bourse filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innogen Pharma's Efsubaglutide Manufacturing Sites Receive Brazil GMP Certification</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnogen Pharma's Efsubaglutide Manufacturing Sites Receive Brazil GMP Certification\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-08-04 13:45</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Guangzhou Innogen Pharmaceutical (HKG:2591) said two contract manufacturing sites for its Efsubaglutide Alfa injection project received good manufacturing practice (GMP) certification from Brazil's health regulator, ANVISA.</p><p>The certification confirms the sites comply with Pharmaceutical Inspection Co-operation Scheme GMP standards and is expected to support commercial production capacity as well as the drug's registration and commercialization in PIC/S member countries, according to a Monday Hong Kong bourse filing.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EWZS","symbol_name":"MSCI巴西小盤股ETF-iShares","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2656824855","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656824855","pubTimestamp":1785822301,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guangzhou Innogen Pharmaceutical  said two contract manufacturing sites for its Efsubaglutide Alfa injection project received good manufacturing practice  certification from Brazil's health regulator, ANVISA.The certification confirms the sites comply with Pharmaceutical Inspection Co-operation Scheme GMP standards and is expected to support commercial production capacity as well as the drug's registration and commercialization in PIC/S member countries, according to a Monday Hong Kong bourse filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EWZS":"MSCI巴西小盘股ETF-iShares","02591":"银诺医药-B","BK1161":"生物科技"},"translate_title":"Innogen Pharma的Efsubaglutide生产基地获得巴西GMP认证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWZS":1.5,"02591":1},"content_text":"Guangzhou Innogen Pharmaceutical (HKG:2591) said two contract manufacturing sites for its Efsubaglutide Alfa injection project received good manufacturing practice (GMP) certification from Brazil's health regulator, ANVISA.The certification confirms the sites comply with Pharmaceutical Inspection Co-operation Scheme GMP standards and is expected to support commercial production capacity as well as the drug's registration and commercialization in PIC/S member countries, according to a Monday Hong Kong bourse filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}